Naked-eye fluorescent sensor for Cu (II) based on indole conjugate BODIPY dye SO Tümay, E Okutan, IF Sengul, E Özcan, H Kandemir, T Doruk, M Çetin, ... Polyhedron 117, 161-171, 2016 | 63 | 2016 |
ETS1 is coexpressed with ZEB2 and mediates ZEB2‐induced epithelial‐mesenchymal transition in human tumors I Yalim‐Camci, P Balcik‐Ercin, M Cetin, G Odabas, N Tokay, AE Sayan, ... Molecular carcinogenesis 58 (6), 1068-1081, 2019 | 32 | 2019 |
The ZEB2‐dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal … R Sreekumar, H Al‐Saihati, M Emaduddin, K Moutasim, M Mellone, ... Molecular Oncology 15 (8), 2065-2083, 2021 | 25 | 2021 |
Cancer stem cells in hepatocellular carcinoma T Yagci, M Cetin, PB Ercin Journal of gastrointestinal cancer 48, 241-245, 2017 | 20 | 2017 |
ROR1 expression and its functional significance in hepatocellular carcinoma cells M Cetin, G Odabas, LR Douglas, PJ Duriez, P Balcik-Ercin, I Yalim-Camci, ... Cells 8 (3), 210, 2019 | 17 | 2019 |
Improved targeting for photodynamic therapy via a biotin–phthalocyanine conjugate: Synthesis, photophysical and photochemical measurements, and in vitro cytotoxicity assay P Balçik-Erçin, M Çetin, M Göksel, M Durmuş New Journal of Chemistry 44 (8), 3392-3401, 2020 | 15 | 2020 |
Genome-wide analysis of endogenously expressed ZEB2 binding sites reveals inverse correlations between ZEB2 and GalNAc-transferase GALNT3 in human tumors P Balcik-Ercin, M Cetin, I Yalim-Camci, G Odabas, N Tokay, AE Sayan, ... Cellular Oncology 41, 379-393, 2018 | 13 | 2018 |
Hepatocellular carcinoma cells with downregulated ZEB2 become resistant to resveratrol by concomitant induction of ABCG2 expression P Balcik-Ercin, M Cetin, I Yalim-Camci, T Uygur, T Yagci Molecular Biology 54, 75-81, 2020 | 10 | 2020 |
Plexin C1 marks liver cancer cells with epithelial phenotype and is overexpressed in hepatocellular carcinoma G Odabas, M Cetin, S Turhal, H Baloglu, AE Sayan, T Yagci Canadian Journal of Gastroenterology and Hepatology 2018, 2018 | 9 | 2018 |
Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification O Saatci, O Akbulut, M Cetin, V Sikirzhytski, M Uner, D Lengerli, ... Cell Death & Differentiation 30 (5), 1305-1319, 2023 | 8 | 2023 |
External complexation of BODIPYs by CB [7] improves in-cell fluorescence imaging MM Ayhan, E Özcan, F Alkan, M Çetin, İ Ün, D Bardelang, B Çoşut Materials Advances 3 (1), 547-553, 2022 | 7 | 2022 |
Naphthalimide-BODIPY dyads: Synthesis, characterization, photophysical properties, live cell imaging and antimicrobial effect H Eserci, M Çetin, F Aydınoğlu, ET Eçik, E Okutan Journal of Molecular Structure 1265, 133440, 2022 | 6 | 2022 |
Doxorubicin induces prolonged DNA damage signal in cells overexpressing DEK isoform-2 E Özçelik, A Kalaycı, B Çelik, A Avcı, H Akyol, İB Kılıç, T Güzel, M Çetin, ... Plos one 17 (10), e0275476, 2022 | 2 | 2022 |
Behavior of HepG2 liver cancer cells using microfluidic-microscopy: A preliminary study H Karamahmutoglu, M Çetin, T Yağcı, M Elitaş Microfluidics, BioMEMS, and Medical Microsystems XVI 10491, 142-146, 2018 | 2 | 2018 |
Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer O Saatci, M Cetin, M Uner, UM Tokat, I Chatzistamou, PG Ersan, ... Nature Communications 14 (1), 6997, 2023 | 1 | 2023 |
Reviving immunogenic cell death upon targeting TACC3 enhances T-DM1 response in HER2-positive breast cancer ME Gedik, O Saatci, N Oberholtzer, M Uner, O Akbulut, M Cetin, M Aras, ... bioRxiv, 2023 | 1 | 2023 |
Psychological, endocrine and polygenic predictors of emotional well-being during the COVID-19 pandemic in a longitudinal birth cohort T Nguyen, L Zillich, M Cetin, ASM Hall, JC Foo, L Sirignano, J Frank, ... Stress 26 (1), 2234060, 2023 | 1 | 2023 |
Abstract LB275: Reactivation of mitotic arrest upon targeting TACC3 restores immunogenic cell death and T-DM1 response in HER2-positive breast cancer O Saatci, ME Gedik, N Oberholtzer, M Uner, O Akbulut, M Cetin, M Aras, ... Cancer Research 84 (7_Supplement), LB275-LB275, 2024 | | 2024 |
Rewiring collagen architecture using a highly potent bi-thiazole inhibitor of LOX mediates chemosensitization in triple-negative breast cancer M Cetin, O Saatci, AH Rezaeian, CN Rao, C Beneker, H Taylor, ... Cancer Research 84 (6_Supplement), 681-681, 2024 | | 2024 |
Targeting PDE4D reinstates toxic PARP trapping via cAMP-ROS-DNA damage axis and restores the efficacy of standard of care in treatment-refractory ER+ breast cancer O Saatci, M Cetin, M Uner, UM Tokat, I Chatzistamou, E Montaudon, ... Cancer Research 84 (6_Supplement), 563-563, 2024 | | 2024 |